<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449512</url>
  </required_header>
  <id_info>
    <org_study_id>2014-20</org_study_id>
    <nct_id>NCT02449512</nct_id>
  </id_info>
  <brief_title>Somatosensory Evoked Potentials From the Lower Urinary Tract</brief_title>
  <official_title>Somatosensory Evoked Potentials From the Lower Urinary Tract in Individuals With Neurogenic Lower Urinary Tract Dysfunction as a Result of Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Paraplegic Centre Nottwil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Paraplegic Centre Nottwil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal cord injury and other systemic neurological diseases (Multiple Sclerosis, Parkinson's&#xD;
      disease) affect the integrity of lower urinary tract (LUT) function, leading to neurogenic&#xD;
      lower urinary tract dysfunction (NLUTD). The urodynamic investigation is the current&#xD;
      &quot;gold-standard&quot; for evaluating LUT function. Nevertheless, the sensory situation of the LUT&#xD;
      cannot be investigated objectively. Furthermore, the current classification of the severity&#xD;
      of the NLUTD due to spinal cord injury (SCI) does not represent the sensory situation of the&#xD;
      LUT. Additional investigations therefore need to be established for assessing the sensory&#xD;
      situation of the LUT. Somatosensory evoked potentials (SEPs) are an established method for&#xD;
      investigating the processing of sensory nervous activity. However, SEPs from the LUT of SCI&#xD;
      individuals have not yet been investigated.&#xD;
&#xD;
      A novel technique, i.e. diffusion tensor imaging (DTI), allows to process magnetic resonance&#xD;
      images (MRI) in order to visualize nerve fibers. Using DTI, the innervation of the bladder&#xD;
      after SCI can be visualized. The structural presentation of bladder innervation will be&#xD;
      compared with the functional results, i.e. the SEP of the LUT in SCI individuals.&#xD;
&#xD;
      The primary objective of the proposed study is to elicit and characterize (latency,&#xD;
      amplitude) the somatosensory evoked potentials (SEPs) from the bladder in individuals&#xD;
      suffering from neurogenic lower urinary tract dysfunction as a result of spinal cord injury.&#xD;
&#xD;
      Furthermore, the SEPs from the bladder will be compared with the SEPs from peripheral nerves&#xD;
      (N. tibialis, N. pudendus, N. medianus).&#xD;
&#xD;
      Moreover, the latency and amplitude of the SEPs from the bladder of individuals with&#xD;
      somato-sensory complete spinal cord injury will be compared with those from the bladder of&#xD;
      individuals with somato-sensory incomplete spinal cord injury.&#xD;
&#xD;
      Finally, the structural innervation of the bladder after SCI will be compared with the&#xD;
      remaining sensory function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Funding issues&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of somatosensory evoked potentials from the bladder</measure>
    <time_frame>within 1 week after enrollment into study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>latency of somatosensory evoked potentials</measure>
    <time_frame>within 1 week after enrollment into study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak-to-peak amplitude of somatosensory evoked potentials</measure>
    <time_frame>within 1 week after enrollment into study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nerve fiber density around bladder</measure>
    <time_frame>within 1 week after enrollment into study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fractional anisotropy of nerve fibers around bladder</measure>
    <time_frame>within 1 week after enrollment into study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent diffusion coefficient of nerve fibers around bladder</measure>
    <time_frame>within 1 week after enrollment into study</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>age</measure>
    <time_frame>1st day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>gender</measure>
    <time_frame>1st day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>severity of spinal cord injury</measure>
    <time_frame>1st day</time_frame>
    <description>American Association of Spinal Cord Injury Impairment Score</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Neurogenic Lower Urinary Tract Dysfunction</condition>
  <arm_group>
    <arm_group_label>complete</arm_group_label>
    <description>individuals with somato-sensory complete spinal cord injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>incomplete</arm_group_label>
    <description>individuals with somato-sensory incomplete spinal cord injury</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        individuals with neurogenic lower urinary tract dysfunction as a result of spinal cord&#xD;
        injury&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
          -  Chronic SCI of a minimum of 1 year&#xD;
&#xD;
          -  Aetiology of SCI: traumatic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years or &gt; 70 years&#xD;
&#xD;
          -  Aetiology of SCI: non-traumatic&#xD;
&#xD;
          -  History of bleeding disorder&#xD;
&#xD;
          -  History of chronic neuropathic pain&#xD;
&#xD;
          -  Intravesical botulinum toxin injections &lt; 12 months ago&#xD;
&#xD;
          -  Bladder management using indwelling catheters (suprapubic, transurethral)&#xD;
&#xD;
          -  Bladder augmentation&#xD;
&#xD;
          -  Sacral deafferentation&#xD;
&#xD;
          -  Sacral neuromodulation&#xD;
&#xD;
          -  Acute, symptomatic urinary tract infection&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Urolithiasis&#xD;
&#xD;
          -  Bladder cancer&#xD;
&#xD;
          -  Exclusion criteria for MRI (cardiac pace maker, implanted metal etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens WÃ¶llner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Paraplegic Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss Paraplegic Centre</name>
      <address>
        <city>Nottwil</city>
        <state>LU</state>
        <zip>CH-6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

